Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

UCSF Health’s Lung Transplant program has been awarded INTERLINK’s 2025 Chairman’s Award for Transplant Excellence as the top-performing lung transplant program in the nation. The UCSF program, which ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 10.90%, which has investors questioning if this is right time to buy.

Volatility and Risk Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

The hospital has introduced the Ion robotic system, a groundbreaking tool designed to improve the detection of small lung ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.